|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We previously reported evidence for association of schizophrenia with SNPs and SNP haplotypes in a region of chromosome 5q containing the SPEC2, PDZ-GEF2 and ACSL6 genes.
|
22205969 |
2011 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
We previously reported evidence for association of schizophrenia with SNPs and SNP haplotypes in a region of chromosome 5q containing the SPEC2, PDZ-GEF2 and ACSL6 genes.
|
22205969 |
2011 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
From these data, we concluded that haplotypes underlying the SPEC2/PDZ-GEF2/ACSL6 region are associated with schizophrenia.
|
17030554 |
2006 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
From these data, we concluded that haplotypes underlying the SPEC2/PDZ-GEF2/ACSL6 region are associated with schizophrenia.
|
17030554 |
2006 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
From these data, we concluded that haplotypes underlying the SPEC2/PDZ-GEF2/ACSL6 region are associated with schizophrenia.
|
17030554 |
2006 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A novel Alzheimer disease locus located near the gene encoding tau protein.
|
25778476 |
2016 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
|
26192919 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
|
26192919 |
2015 |
|
Malignant neoplasm of endometrium
|
0.060 |
Biomarker
|
disease |
BEFREE |
Twelve type I (AN3, ECC-1, EN, EN-1, EN-11, HEC-1A, HEC1B, Ishikawa, KLE, MFE-280, MFE-296, MFE-319) and four type II (ARK1, ARK2, HEC-155/180, SPEC-2) endometrial cancer cell lines were studied.
|
30107158 |
2019 |
|
Endometrial Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Twelve type I (AN3, ECC-1, EN, EN-1, EN-11, HEC-1A, HEC1B, Ishikawa, KLE, MFE-280, MFE-296, MFE-319) and four type II (ARK1, ARK2, HEC-155/180, SPEC-2) endometrial cancer cell lines were studied.
|
30107158 |
2019 |
|
Malignant neoplasm of endometrium
|
0.060 |
Biomarker
|
disease |
BEFREE |
Five different EC cell lines (Ishikawa, Hec-1B, KLE, ARK-2, and SPEC-2) representing different histologies, grades of EC, sensitivity to cisplatin and p53 status were used for the in vitro studies.
|
28545688 |
2017 |
|
Endometrial Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Five different EC cell lines (Ishikawa, Hec-1B, KLE, ARK-2, and SPEC-2) representing different histologies, grades of EC, sensitivity to cisplatin and p53 status were used for the in vitro studies.
|
28545688 |
2017 |
|
Malignant neoplasm of endometrium
|
0.060 |
Biomarker
|
disease |
BEFREE |
Infectivity of VVNIS-C and VVNIS-W in type I (HEC1A, Ishikawa, KLE, RL95-2, and AN3 CA) and type II (ARK-1, ARK-2, and SPEC-2) human EC cell lines was evaluated.
|
24434058 |
2014 |
|
Endometrial Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Infectivity of VVNIS-C and VVNIS-W in type I (HEC1A, Ishikawa, KLE, RL95-2, and AN3 CA) and type II (ARK-1, ARK-2, and SPEC-2) human EC cell lines was evaluated.
|
24434058 |
2014 |
|
Malignant neoplasm of endometrium
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We explored whether Acrp30 could reverse the leptin-induced metastasis phenotype in the SPEC-2 endometrial cancer cell line.
|
22327423 |
2012 |
|
Endometrial Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We explored whether Acrp30 could reverse the leptin-induced metastasis phenotype in the SPEC-2 endometrial cancer cell line.
|
22327423 |
2012 |
|
Malignant neoplasm of endometrium
|
0.060 |
Biomarker
|
disease |
BEFREE |
A focused, real time PCR array was performed comparing a papillary serous (SPEC2) and an endometrioid (Ishikawa) endometrial cancer cell line.
|
19476987 |
2009 |
|
Endometrial Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
A focused, real time PCR array was performed comparing a papillary serous (SPEC2) and an endometrioid (Ishikawa) endometrial cancer cell line.
|
19476987 |
2009 |
|
Malignant neoplasm of endometrium
|
0.060 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
|
10656459 |
2000 |
|
Endometrial Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
|
10656459 |
2000 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the combined analyses, we discovered two novel loci associated with CRC: rs12522693 at 5q23.3 (CDC42SE2-CHSY3, OR = 1.31, P = 2.08 × 10-8) and rs17836917 at 17q12 (ASIC2-CCL2, OR = 0.75, P = 4.55 × 10-8).
|
26515597 |
2015 |
|
Uterine Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
In orthotopic mouse models of uterine cancer, 3G3 monotherapy had significant antitumor effects in the PDGFRα-positive models (Hec-1A, Ishikawa, Spec-2) but not in the PDGFRα-negative model (OVCA432).
|
24634380 |
2014 |